OVID: Jeremy Levin reports 4.5% stake

Ovid Therapeutics Inc. reports that Jeremy M. Levin beneficially owns 8,551,502 shares of the company's common stock, equal to 4.5% of the class.

Rhea-AI Filing Summary

Ovid Therapeutics Inc. reports that Jeremy M. Levin beneficially owns 8,551,502 shares of the company's common stock, equal to 4.5% of the class. The filing breaks this position into direct holdings, entity holdings, warrants, and options exercisable within 60 days of March 31, 2026.

The outstanding share base used to calculate the percentage is 186,640,102 shares as reported in the company's Form 10-Q for the quarter ended March 31, 2026.

Insights

Corporate Governance Expert

Levin holds a mid-single-digit ownership stake with exercisable options included.

Jeremy M. Levin reports beneficial ownership of 8,551,502 shares, representing 4.5% of the outstanding common stock based on 186,640,102 shares outstanding as of March 31, 2026. The position combines direct holdings, a small family LLC holding, 35,500 Series B warrants, and 4,745,493 options exercisable within 60 days.

Because the percentage is below 5% and includes exercisable derivatives, the position is regulatory-level disclosure of significant insider holdings but does not by itself indicate a controlling stake. Subsequent filings will show any changes in exercise or dispositions.

Key Figures

Beneficially owned: 8,551,502 shares Percent of class: 4.5% Shares outstanding: 186,640,102 shares +4 more

7 metrics

Beneficially owned 8,551,502 shares as of filing (aggregate holdings)

Percent of class 4.5% based on 186,640,102 shares outstanding as of 03/31/2026

Shares outstanding 186,640,102 shares as reported in Form 10-Q for quarter ended 03/31/2026

Directly held shares 3,735,048 shares held directly by Reporting Person

Divo Holdings LLC 35,461 shares held by entity managed by Reporting Person's spouse

Series B warrants 35,500 shares issuable upon exercise

Options exercisable 4,745,493 shares issuable upon exercise within 60 days of 03/31/2026

Key Terms

beneficially owns, Series B warrants, options exercisable within 60 days

3 terms

beneficially owns regulatory

"As of the date hereof, the Reporting Person beneficially owns 8,551,502 shares"

Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.

Series B warrants financial

"35,500 shares of common stock issuable upon exercise of Series B warrants"

Series B warrants are contracts issued alongside a company's Series B financing that give the holder the right to buy a set number of shares at a fixed price within a specified time. For investors, they matter because they can provide leveraged upside if the company grows, or they can dilute existing shareholders when exercised—like a coupon promising a future share at a known price that can add value or change ownership stakes.

options exercisable within 60 days financial

"4,745,493 shares of common stock issuable upon the exercise of stock options within 60 days"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Jeremy M. Levin report in OVID?

Mr. Levin reports beneficial ownership of 8,551,502 shares, representing 4.5% of OVID's common stock, calculated using 186,640,102 shares outstanding as of March 31, 2026.

How is Levin's 8,551,502-share position composed?

The position includes 3,735,048 shares held directly, 35,461 shares held by Divo Holdings, LLC, 35,500 Series B warrants, and 4,745,493 options exercisable within 60 days of March 31, 2026.

What outstanding share count was used to compute the 4.5% figure?

The percentage is based on 186,640,102 shares outstanding, as reported in OVID's Form 10-Q for the quarter ended March 31, 2026, which the filing cites for the calculation.

Does this Schedule 13G/A indicate a change of control at OVID?

No; the filing discloses a 4.5% beneficial stake below the 5% threshold for larger blocks and combines direct holdings and exercisable derivatives, not indicating control or majority ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 04:27 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 6)

OVID THERAPEUTICS INC.

(Name of Issuer)

COMMON STOCK, $0.001 PAR VALUE

(Title of Class of Securities)

690469101

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 690469101

1

Names of Reporting Persons

Jeremy M. Levin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 8,551,502.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 8,551,502.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,551,502.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.5 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: OVID THERAPEUTICS INC.
(b)	Address of issuer's principal executive offices: 441 Ninth Avenue, 14th Floor, New York, NY, 10001.
Item 2.
(a)	Name of person filing: Jeremy M. Levin (the "Reporting Person")
(b)	Address or principal business office or, if none, residence: c/o Ovid Therapeutics Inc. 441 Ninth Avenue, 14th Floor New York, New York 10001
(c)	Citizenship: United States of America
(d)	Title of class of securities: COMMON STOCK, $0.001 PAR VALUE
(e)	CUSIP No.: 690469101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of the date hereof, the Reporting Person beneficially owns 8,551,502 shares of the Issuer's common stock, which consists of (i) 3,735,048 shares of the Issuer's common stock held directly by the Reporting Person, (ii) 35,461 shares held by Divo Holdings, LLC, a limited liability company managed by the Reporting Person's spouse, (iii) 35,500 shares of common stock issuable upon exercise of Series B warrants, and (iv) 4,745,493 shares of common stock issuable upon the exercise of stock options within 60 days of March 31, 2026.
(b)	Percent of class: As of the date hereof, the Reporting Person holds 4.5% of the Issuer's common stock. This percentage is calculated based upon 186,640,102 outstanding shares of the Issuer's common stock, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 (Commission File No. 001-38085) filed with the Securities and Exchange Commission on May 12, 2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 8,551,502 shares
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 8,551,502 shares
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Jeremy M. Levin

Signature:	/s/ Jeremy M. Levin
Name/Title:	Jeremy M. Levin
Date:	05/14/2026